Trial Profile

A study evaluating treatment persistence and adherence with mirabegron vs antimuscarinics in overactive bladder patients.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirabegron (Primary) ; Fesoterodine; Oxybutynin; Solifenacin; Tolterodine; Trospium chloride
Indications Overactive bladder
Focus Therapeutic Use

Most Recent Events

19 Sep 2017 New trial record
14 Sep 2017 Primary endpoint (Persistence on therapy) has been met.
14 Sep 2017 Results published in the International Journal of Clinical Practice

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com